المؤلفون: Kelley, RK, Nimeiri, HS, Munster, PN, Vergo, MT, Huang, Y, Li, C-M, Hwang, J, Mulcahy, MF, Yeh, BM, Kuhn, P, Luttgen, MS, Grabowsky, JA, Stucky-Marshall, L, Korn, WM, Ko, AH, Bergsland, EK, Benson, AB, Venook, AP

المصدر: Annals of Oncology. 24(7)

مصطلحات موضوعية: Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Digestive Diseases, Cancer, Liver Disease, Clinical Trials and Supportive Activities, Clinical Research, Liver Cancer, Rare Diseases, 6.1 Pharmaceuticals, 6.2 Cellular and gene therapies, Evaluation of treatments and therapeutic interventions, Aged, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Biomarkers, Tumor, Carcinoma, Hepatocellular, Disease-Free Survival, Drug Administration Schedule, Female, Humans, Liver Neoplasms, Male, Maximum Tolerated Dose, Middle Aged, Neoplastic Cells, Circulating, Niacinamide, Phenylurea Compounds, Protein Precursors, Prothrombin, Sirolimus, Sorafenib, Treatment Outcome, alpha-Fetoproteins, hepatocellular carcinoma, mTOR, pharmacokinetics, sorafenib, temsirolimus, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis

وصف الملف: application/pdf

URL الوصول: https://escholarship.org/uc/item/335599qj

المؤلفون: Kircher SM, Benson AB 3rd, Farber M, Nimeiri HS

المصدر: Journal of Clinical Oncology; 2/10/2012, Vol. 30 Issue 5, p548-553, 6p

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Kunz PL; Yale School of Medicine, New Haven, CT., Graham NT; Dana-Farber Cancer Institute, Boston, MA., Catalano PJ; Dana-Farber Cancer Institute, Boston, MA., Nimeiri HS; Robert H. Lurie Cancer Center of Northwestern University, Chicago, IL., Fisher GA; Stanford University School of Medicine, Stanford, CA., Longacre TA; Stanford University School of Medicine, Stanford, CA., Suarez CJ; Stanford University School of Medicine, Stanford, CA., Martin BA; University of Louisville, Louisville, KY., Yao JC; University of Texas MD Anderson Cancer Center, Houston, TX., Kulke MH; Boston University/Boston Medical Center, Boston, MA., Hendifar AE; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA., Shanks JC; Health East Cancer Care, Lake Elmo, MN., Shah MH; The Ohio State University Comprehensive Cancer Center, Columbus, OH., Zalupski MM; University of Michigan, Ann Arbor, MI., Schmulbach EL; The Permanente Medical Group, South San Francisco, CA., Reidy-Lagunes DL; Weill Cornell Medical College, New York, NY., Strosberg JR; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL., O'Dwyer PJ; University of Pennsylvania Abramson Cancer Center, Philadelphia, PA., Benson AB 3rd; Robert H. Lurie Cancer Center of Northwestern University, Chicago, IL.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Mar 01; Vol. 41 (7), pp. 1359-1369. Date of Electronic Publication: 2022 Oct 19.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Neuroendocrine Tumors*/drug therapy , Pancreatic Neoplasms*/drug therapy, Humans ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Capecitabine/therapeutic use ; Dacarbazine/therapeutic use ; Prospective Studies ; Retrospective Studies ; Temozolomide/therapeutic use ; Treatment Outcome

المؤلفون: Cannon TL; Inova Schar Cancer Institute., Randall JN BA; Inova Schar Cancer Institute., Sokol ES; Foundation Medicine., Alexander SM; MS, CRNP, AOCNP Foundation Medicine., Wadlow RC; Inova Schar Cancer Institute., Winer AA; Inova Schar Cancer Institute., Barnett DM; Virginia Commonwealth University., Rayes DL BS; University of Virginia., Nimeiri HS; Foundation Medicine., McGregor KA; Foundation Medicine.

المصدر: Cancer treatment and research communications [Cancer Treat Res Commun] 2022; Vol. 32, pp. 100569. Date of Electronic Publication: 2022 Apr 30.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 101694651 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2468-2942 (Electronic) Linking ISSN: 24682942 NLM ISO Abbreviation: Cancer Treat Res Commun Subsets: MEDLINE

مواضيع طبية MeSH: Colorectal Neoplasms*/diagnosis , Colorectal Neoplasms*/genetics , Colorectal Neoplasms*/secondary , Proto-Oncogene Proteins B-raf*/genetics, Colonic Neoplasms/diagnosis ; Colonic Neoplasms/genetics ; Colonic Neoplasms/secondary ; Genes, BRCA1 ; Genes, BRCA2 ; Humans ; Microsatellite Instability ; Mutation ; Prevalence ; Prognosis ; Prospective Studies ; Rectal Neoplasms/diagnosis ; Rectal Neoplasms/genetics ; Rectal Neoplasms/secondary

المؤلفون: Kelley RK; Helen Diller Family Comprehensive Cancer Center (HDFCCC), University of California, San Francisco (UCSF), San Francisco, California, USA., Joseph NM; Department of Pathology, University of California, San Francisco (UCSF), San Francisco, California, USA., Nimeiri HS; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA., Hwang J; Helen Diller Family Comprehensive Cancer Center (HDFCCC), University of California, San Francisco (UCSF), San Francisco, California, USA., Kulik LM; Division of Hepatology, Department of Medicine, Northwestern University, Chicago, Illinois, USA., Ngo Z; Helen Diller Family Comprehensive Cancer Center (HDFCCC), University of California, San Francisco (UCSF), San Francisco, California, USA., Behr SC; Department of Radiology, University of California, San Francisco (UCSF), San Francisco, California, USA., Onodera C; Clinical Cancer Genomics Lab, UCSF Health, San Francisco, California, USA., Zhang K; Helen Diller Family Comprehensive Cancer Center (HDFCCC), University of California, San Francisco (UCSF), San Francisco, California, USA., Bocobo AG; Helen Diller Family Comprehensive Cancer Center (HDFCCC), University of California, San Francisco (UCSF), San Francisco, California, USA., Benson AB; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA., Venook AP; Helen Diller Family Comprehensive Cancer Center (HDFCCC), University of California, San Francisco (UCSF), San Francisco, California, USA., Gordan JD; Helen Diller Family Comprehensive Cancer Center (HDFCCC), University of California, San Francisco (UCSF), San Francisco, California, USA.

المصدر: Liver cancer [Liver Cancer] 2021 Sep 06; Vol. 10 (6), pp. 561-571. Date of Electronic Publication: 2021 Sep 06 (Print Publication: 2021).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: S. Karger Country of Publication: Switzerland NLM ID: 101597993 Publication Model: eCollection Cited Medium: Print ISSN: 2235-1795 (Print) Linking ISSN: 16645553 NLM ISO Abbreviation: Liver Cancer Subsets: PubMed not MEDLINE

المؤلفون: Israel MA; Foundation Medicine Inc., Cambridge, Massachusetts, USA., Danziger N; Foundation Medicine Inc., Cambridge, Massachusetts, USA., McGregor KA; Foundation Medicine Inc., Cambridge, Massachusetts, USA., Murugesan K; Foundation Medicine Inc., Cambridge, Massachusetts, USA., Gjoerup O; Foundation Medicine Inc., Cambridge, Massachusetts, USA., Sokol ES; Foundation Medicine Inc., Cambridge, Massachusetts, USA., Tukachinsky H; Foundation Medicine Inc., Cambridge, Massachusetts, USA., Kurzrock R; Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, University of California, San Diego Moores Cancer Center, La Jolla, California, USA.; Department of Medicine, Division of Hematology and Oncology, University of California, San Diego, San Diego, California, USA., Kato S; Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, University of California, San Diego Moores Cancer Center, La Jolla, California, USA.; Department of Medicine, Division of Hematology and Oncology, University of California, San Diego, San Diego, California, USA., Sicklick JK; Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, University of California, San Diego Moores Cancer Center, La Jolla, California, USA.; Department of Surgery, Division of Surgical Oncology, University of California, San Diego, San Diego, California, USA., Nimeiri HS; Foundation Medicine Inc., Cambridge, Massachusetts, USA., Oxnard GR; Foundation Medicine Inc., Cambridge, Massachusetts, USA., Ross JS; Foundation Medicine Inc., Cambridge, Massachusetts, USA.; Departments of Urology and Pathology, SUNY Upstate Medical University, Syracuse, New York, USA.

المصدر: The oncologist [Oncologist] 2021 Sep; Vol. 26 (9), pp. 787-796. Date of Electronic Publication: 2021 Jun 18.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

مواضيع طبية MeSH: Bile Duct Neoplasms*/diagnosis , Bile Duct Neoplasms*/genetics , Cholangiocarcinoma*/diagnosis , Cholangiocarcinoma*/genetics, Bile Ducts, Intrahepatic ; Biopsy ; Genomics ; Humans

المؤلفون: Brown JC; Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA.; LSU Health Sciences Center, New Orleans School of Medicine, New Orleans, LA 70012, USA.; Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70012, USA., Rosenthal MH; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA., Ma C; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA., Zhang S; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA., Nimeiri HS; Division of Hematology Oncology, Department of Medicine, Northwestern University, Chicago, IL 60611, USA., McCleary NJ; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA., Abrams TA; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA., Yurgelun MB; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA., Cleary JM; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA., Rubinson DA; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA., Schrag D; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA., Bullock AJ; Beth Israel Deaconess Medical Center, Boston, MA 02215, USA., Allen J; Massachusetts General Hospital, Boston, MA 02114, USA., Zuckerman D; St Luke's Mountain States Tumor Institute, Boise, ID 83712, USA., Chan E; Vanderbilt University Medical Center, Nashville, TN 37232, USA., Chan JA; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA., Wolpin B; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA., Constantine M; Dana-Farber at Milford Regional Medical Center, Milford, MA 01757, USA., Weckstein DJ; New Hampshire Oncology Hematology, Hookset, NH 03106, USA., Faggen MA; Dana-Farber at South Shore Hospital, South Weymouth, MA 02190, USA., Thomas CA; New England Cancer Specialists, Scarborough, ME 04074, USA., Kournioti C; Newton-Wellesley Hospital, Newton, MA 02462, USA., Yuan C; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA., Zheng H; Massachusetts General Hospital, Boston, MA 02114, USA., Hollis BW; Department of Pediatrics, Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA., Fuchs CS; Yale Cancer Center, New Haven, CT 06510, USA., Ng K; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA., Meyerhardt JA; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.

المصدر: Cancers [Cancers (Basel)] 2020 Nov 20; Vol. 12 (11). Date of Electronic Publication: 2020 Nov 20.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE

المؤلفون: Ng K; Dana-Farber Cancer Institute, Boston, Massachusetts., Nimeiri HS; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois., McCleary NJ; Dana-Farber Cancer Institute, Boston, Massachusetts., Abrams TA; Dana-Farber Cancer Institute, Boston, Massachusetts., Yurgelun MB; Dana-Farber Cancer Institute, Boston, Massachusetts., Cleary JM; Dana-Farber Cancer Institute, Boston, Massachusetts., Rubinson DA; Dana-Farber Cancer Institute, Boston, Massachusetts., Schrag D; Dana-Farber Cancer Institute, Boston, Massachusetts., Miksad R; Beth Israel Deaconess Medical Center, Boston, Massachusetts., Bullock AJ; Beth Israel Deaconess Medical Center, Boston, Massachusetts., Allen J; Massachusetts General Hospital, Boston., Zuckerman D; St Luke's Mountain States Tumor Institute, Boise, Idaho., Chan E; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee., Chan JA; Dana-Farber Cancer Institute, Boston, Massachusetts., Wolpin BM; Dana-Farber Cancer Institute, Boston, Massachusetts., Constantine M; Dana-Farber at Milford Regional Medical Center, Milford, Massachusetts., Weckstein DJ; New Hampshire Oncology Hematology, Hookset., Faggen MA; Dana-Farber at South Shore Hospital, South Weymouth, Massachusetts., Thomas CA; New England Cancer Specialists, Scarborough, Maine., Kournioti C; Newton-Wellesley Hospital, Newton, Massachusetts., Yuan C; Dana-Farber Cancer Institute, Boston, Massachusetts., Ganser C; Dana-Farber Cancer Institute, Boston, Massachusetts., Wilkinson B; Dana-Farber Cancer Institute, Boston, Massachusetts., Mackintosh C; Dana-Farber Cancer Institute, Boston, Massachusetts., Zheng H; Massachusetts General Hospital, Boston., Hollis BW; Medical University of South Carolina, Charleston., Meyerhardt JA; Dana-Farber Cancer Institute, Boston, Massachusetts., Fuchs CS; Yale Cancer Center, New Haven, Connecticut.

المصدر: JAMA [JAMA] 2019 Apr 09; Vol. 321 (14), pp. 1370-1379.

نوع المنشور: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 7501160 Publication Model: Print Cited Medium: Internet ISSN: 1538-3598 (Electronic) Linking ISSN: 00987484 NLM ISO Abbreviation: JAMA Subsets: MEDLINE

مواضيع طبية MeSH: Dietary Supplements* , Progression-Free Survival*, Adenocarcinoma/*drug therapy , Cholecalciferol/*administration & dosage , Colorectal Neoplasms/*drug therapy , Vitamins/*administration & dosage, Adenocarcinoma/mortality ; Adenocarcinoma/secondary ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cholecalciferol/adverse effects ; Colorectal Neoplasms/mortality ; Colorectal Neoplasms/secondary ; Dose-Response Relationship, Drug ; Double-Blind Method ; Female ; Humans ; Male ; Middle Aged ; Multivariate Analysis ; Neoplasm Staging ; Proportional Hazards Models ; Vitamin D/analogs & derivatives ; Vitamin D/blood ; Vitamins/adverse effects

المؤلفون: Sahai V; Department of Internal Medicine, University of Michigan, Ann Arbor., Catalano PJ; Dana-Farber Cancer Institute, Boston, Massachusetts., Zalupski MM; Department of Internal Medicine, University of Michigan, Ann Arbor., Lubner SJ; University of Wisconsin Carbone Cancer Center, Madison., Menge MR; Frauenshuh Cancer Center, Park Nicollet Health Services, Minneapolis, Minnesota., Nimeiri HS; Robert H. Lurie Cancer Center of Northwestern University, Chicago, Illinois., Munshi HG; Robert H. Lurie Cancer Center of Northwestern University, Chicago, Illinois., Benson AB 3rd; Robert H. Lurie Cancer Center of Northwestern University, Chicago, Illinois., O'Dwyer PJ; Abramson Cancer Center, University of Pennsylvania, Philadelphia.

المصدر: JAMA oncology [JAMA Oncol] 2018 Dec 01; Vol. 4 (12), pp. 1707-1712.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study

بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Albumins/*administration & dosage , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Bile Duct Neoplasms/*drug therapy , Cholangiocarcinoma/*drug therapy , Deoxycytidine/*analogs & derivatives , Paclitaxel/*administration & dosage, Administration, Intravenous ; Adult ; Aged ; Aged, 80 and over ; Albumins/adverse effects ; Bile Duct Neoplasms/mortality ; Bile Duct Neoplasms/pathology ; Bile Ducts, Intrahepatic/pathology ; Cholangiocarcinoma/mortality ; Cholangiocarcinoma/pathology ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Disease Progression ; Female ; Humans ; Male ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Metastasis ; Paclitaxel/adverse effects ; Treatment Outcome ; Gemcitabine